The influence of clinical, pathological and surgical factors on the occurrence of recurrence of borderline ovarian tumors in different age groups

Cover Page

Cite item

Full Text

Abstract

Background. Borderline ovarian tumors (BOT), due to their unclear biological potential, remain a problem for oncogynecologists. On the one hand, frequent recurrences of tumors, and on the other hand, a high survival rate in the diagnosis of patients requires careful weighing of all risk factors when choosing surgical intervention tactics in patients with BOT. A large number of recurrences of BOT in patients of fertile age lead to disability of patients, deterioration of their quality of life and loss of reproductive function.

Objective: evaluation of the influence of clinical and morphological factors (the presence of non-invasive implants, bilateral lesion of the ovaries, the presence of psammous bodies and malignization tricks) and surgical factors (damage to the cyst capsule and carrying out fertility preserving operations) on the recurrence of BOT in various age groups.

Materials and methods. The material for the study was the protocols of an in vivo pathoanatomical study of a biopsy (surgical) material obtained from patients with a diagnosis of BOT for the period from 2000 to 2017 inclusive, according to the Regional Forensic Medical Bureau of Kursk. A total of 110 protocols for the first occurrence of BOT and 14 protocols for the tumor recurrences were analyzed. The age of patients undergoing an in vivo pathologic examination ranged from 19 to 75 years.

Results and conclusions. It has been revealed that psammous bodies, fertility preserving operations and reproductive age are associated with tumor recurrence. Groups of patients with foci of malignancy and bilateral lesions have a lower risk of BOT recurrence due to the radical surgical treatment tactics and possibly the use of chemotherapy in the first case. Non-invasive implants are not associated with the risk of BOT recurrence.

About the authors

F. V. Novikov

Kursk State Medical University, Ministry of Health of Russia

3 Karl Marx St., 305041 Kursk Russian Federation

V. P. Bondarev

Regional Forensic Medical Bureau

45A Sumskaya St., Kursk 305007 Russian Federation

E. S. Mishina

Kursk State Medical University, Ministry of Health of Russia; Kursk Regional Clinical Oncology Dispensary

Author for correspondence.
Email: katusha100390@list.ru
ORCID iD: 0000-0003-3835-0594

3 Karl Marx St., 305041 Kursk;

1 Eliseeva St., khutor Kislino, Ryshkovskiy selsovet, Kursk region 305524

Russian Federation

M. V. Mnikhovich

Research Institute of Human Morphology; Pirogov Russian National Research Medical University, Ministry of Health of Russia

ORCID iD: 0000-0001-7147-7912

3 Tsyurupy St., 117418 Moscow; 1 Ostrovityanova St., 117997 Moscow

Russian Federation

References

  1. Makarewicz H., Emerich J., Olszewski J. Comparison of two groups of patients with serous and mucinous types of borderline ovarian tumors. Ginekol Pol 2003;74(1):24–31.
  2. Hauptmann S., Friedrich K., Redline R. et al. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 2017;470(2):125–42. doi: 10.1007/s00428-016-2040-8.
  3. Trillsch F., Ruetzel J.D., Herwig U. et al. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (borderline ovarian tumor). J Ovar Res 2013;6(1):48. doi: 10.1186/1757-2215-6-48.
  4. Akeson M., Zetterqvist B.M., Dahllof K. et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Obstet 2008;18(3): 453–9. doi: 10.1111/j.1525-1438.2007.01051.x.
  5. Heintz A.P., Odicino F., Maisonneuve P. et al. Carcinoma of the ovary. FIGO 26 th annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 2006;95(suppl 1):S161–92. doi: 10.1016/S0020-7292(06)60033-7.
  6. Ureyen I., Karalok A., Tasci T. et al. The factors predicting recurrence in patients with serous borderline ovarian tumor. Int J Gynecol сancer 2016;26(1):66–72. doi: 10.1097/IGC.0000000000000568.
  7. Helpman L., Beiner M.E., Aviel-Ronen S. et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril 2015;104:138–44. doi: 10.1016/j.fertnstert.2015.03.038.
  8. Levine J., Canada A., Stern C.J. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010;28:4831–41. doi: 10.1200/JCO.2009.22.8312.
  9. Uzan C., Nikpayam M., Ribassin-Majed L. et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol 2014;25:1312–9. doi: 10.1093/annonc/mdu139.
  10. Davydova I.Yu., Karseladze A.I., Kuznetsov V.V. et al. Practical recommendations for the treatment of borderline ovarian tumors. Malignant tumors: practical recommendations RUSSCO № 3s2, 2018. Vol. 8. Pp. 171–177. Available at: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-11.pdf. (In Russ.)
  11. Seidman J.D., Kurman R.J. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31(5): 539–57.
  12. Vinogradov I.I., Andreeva Yu.Yu., Novikova E.G. et al. Clinical and morphological prognostic factors in borderline ovarian tumors. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2014;3:22–5. (In Russ.)
  13. Cheng E.J., Kurman R.J.,Wang M. et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 2004;84(6):778–84. doi: 10.1038/labinvest.3700103.
  14. Novikova, E.G., Andreev Yu.Yu., Shevchuk A.S. Borderline ovarian tumors. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2013;1:84–91. (In Russ.)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.